The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.

Suresh S.  Ramalingam

Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Novartis

Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer

James Chih-Hsin  Yang

Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche Pharma AG

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Clovis Oncology; Daiichi Sankyo; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Takeda (Inst)

Research Funding - Boehringer Ingelheim (Inst)

Chee Khoon  Lee

No Relationships to Disclose

Takayasu  Kurata

Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma

Research Funding - AstraZeneca; Chugai Pharma

Dong-Wan  Kim

Consulting or Advisory Role - Novartis

Thomas  John

Consulting or Advisory Role - AstraZeneca

Travel, Accommodations, Expenses - Boehringer Ingelheim; Roche Pharma AG

Naoyuki  Nogami

Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Nippon Boehringer Ingelheim; Pfizer; Taiho Pharmaceutical

Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)

Yuichiro  Ohe

Honoraria - AstraZeneca

Research Funding - AstraZeneca (Inst)

Yuri  Rukazenkov

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Paul  Frewer

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Mireille  Cantarini

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Serban  Ghiorghiu

Employment - AstraZeneca; AstraZeneca (I)

Stock and Other Ownership Interests  - AstraZeneca; AstraZeneca (I)

Pasi A.  Janne

Stock and Other Ownership Interests  - Gatekeeper Pharmaceuticals

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Clovis Oncology; Genentech; Merrimack; Pfizer; Roche Pharma AG; Sanofi

Other Relationship - LabCorp